Today our CEO Alise Reicin, MD will give a corporate presentation at the TD Cowen Health Care Conference in Boston. You can access the webcast for 30 days at: https://lnkd.in/etQmUSf4
Tectonic Therapeutic, Inc.
生物技术
Watertown，Massachusetts 4,261 位关注者
Transforming the discovery of novel GPCR-targeted therapies
关于我们
Tectonic is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-Protein Coupled Receptors. We have developed a proprietary technology platform called GEODe? to enable the discovery and development of GPCR-targeted biologic medicines that can modify the course of disease, by addressing challenges that have limited the pace of innovation in this field. Our focus is on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life.
- 网站
-
https://www.tectonictx.com
Tectonic Therapeutic, Inc.的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- Watertown，Massachusetts
- 类型
- 上市公司
- 创立
- 2019
地点
-
主要
获取路线
490 Arsenal Way
Suite 210
US，Massachusetts，Watertown，02472
Tectonic Therapeutic, Inc.员工
-
Christian Cortis
COO/CFO at Stealth NewCo | Strategic Advisor
-
Craig R. Ulmer
Global Program/Project Management
-
Phillip Donenberg
Member of the Board of Directors and Audit Committee Chairman at Taysha Gene Therapies and Tectonic Therapeutic
-
Ximena Barros-álvarez, Ph.D.
Project Team Leader | SBDD | Biologics and Small molecules | Biochemistry and Structural Biology | Fulbrighter | DEIB advocate | LatinaInSTEM
动态
-
Today is #RareDiseaseDay, raising awareness about the 6,000 rare diseases that impact up to 5% of the global population. Our pipeline includes work targeting one of these rare diseases, Hereditary Hemorrhagic Telangiectasia (HHT), which affects 1 in 5000 people worldwide. https://lnkd.in/gk6hbAF
-
-
Today our CEO Alise Reicin, MD will co-moderate a panel with her sister Cheryl Reicin, Partner and International Chair of Life Sciences at Mintz. Hosted by the Biotech CEO Sisterhood and Mintz, the panel features execs from Eli Lilly, Merck, Novo Nordisk, and Vertex, who will discuss successfully executing and structuring life sciences M&A and licensing transactions and partnering with big pharma. https://lnkd.in/grUr4bA2
-
-
We're recognizing #BlackHistoryMonth in February. This quote from black engineer and inventor Gerald "Jerry" Lawson is particularly apt for the way we think about drug development: “Explore new vistas, new avenues, new ways — not relying on everyone else’s way to tell you which way to go.” The first two drugs in our pipeline are being developed for indications without any approved therapy (Group 2 Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia.)
-
-
February 9-15 is Heart Failure Awareness Week to spread the word about #heartfailure, which strikes nearly 7 million Americans over 20 years old. This week strengthens our dedication to develop novel treatments for patients with Pulmonary Hypertension associated with Left Heart failure for whom there are no approved therapies #HFWeek2025 Learn more: https://lnkd.in/eTrWmg7u
-
-
On International Day of Women and Girls in Science, we honor the talented women at Tectonic. Through both their leadership and scientific expertise they are driving our innovation and progress while inspiring the next generation of female scientists and leaders. #February11 #WomenInScience #equalityinscience https://lnkd.in/eUnAYyp3
-
-
We’re recognizing American #HeartMonth in February, helping raise awareness of #cardiovasculardisease, the leading cause of death in the US. We’re proud to be developing TX45, our lead candidate, for pulmonary hypertension associated with left heart failure. #Group2PAH
-
-
We are excited to announce this financing news today. https://lnkd.in/e5TetESr
-
-
We are pleased to announce positive interim Phase 1b for our lead program, TX45. https://lnkd.in/epKqEJ4B
-
-
We will host a conference call and webcast on the interim Phase 1b for our lead program, TX45, today at 8 a.m. ET. Join the call here: https://lnkd.in/etQmUSf4
-